Exelixis (EXEL) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Exelixis (EXEL) has outperformed Bio-Techne (TECH) over the past year, gaining 47.5% versus a gain of 22.5%. Over five years, EXEL leads with a +167.8% price change compared with -41.7% for TECH. Exelixis is the larger company by market cap ($14.48 billion vs $11.37 billion), about 1.3 times the size.
On valuation, Exelixis trades at a lower forward P/E (13.8x vs 31.4x for Bio-Techne). Bio-Techne pays a dividend yielding 0.44%, while Exelixis does not currently pay one. Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 15.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | TECH |
|---|---|---|
| Share price | $58.44 | $72.53 |
| Market cap | $14.48B | $11.37B |
| 1-day change | +0.19% | +0.14% |
| YTD return | +33.33% | +23.33% |
| 1-year return | +47.46% | +22.54% |
| 5-year return | +167.83% | -41.75% |
| P/E ratio (TTM) | 18.44 | 62.53 |
| Forward P/E | 13.78 | 31.36 |
| EPS (TTM) | $3.17 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $2.32B | $1.22B |
| Revenue growth (YoY) | +6.98% | -0.38% |
| Net income (latest FY) | $782.57M | $181.86M |
| Gross margin | 96.39% | 65.77% |
| Operating margin | 37.59% | 20.73% |
| Net margin | 33.73% | 14.97% |
| 52-week high | $61.14 | $72.69 |
| 52-week low | $33.76 | $43.20 |
| Distance from 52-week high | -4.42% | -0.22% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -6.69% | -2.80% |
| Average volume | 2.33M | 3.08M |
| Shares outstanding | 247.78M | 156.82M |
| Employees | 1,077 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXEL has outperformed TECH by 24.9 percentage points over the past year.
- Bio-Techne trades at a higher earnings multiple (62.5x vs 18.4x trailing P/E).
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 15.0 cents for Bio-Techne.
- Exelixis grew revenue faster in its latest fiscal year (+6.98% vs -0.38%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
EXEL vs TECH FAQ
Which is bigger, Exelixis or Bio-Techne?
Exelixis (EXEL) is larger, with a market capitalization of $14.48B compared with $11.37B for Bio-Techne (TECH).
Which stock has performed better over the past year, EXEL or TECH?
EXEL returned +47.46% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or TECH?
EXEL has the lower trailing P/E at 18.4, versus 62.5 for TECH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Exelixis or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Exelixis does not currently pay a regular dividend.
Are Exelixis and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.